GSK invests over USD1B in Frontier Biotechnologies’ RNA-based kidney disease therapies

UK—GSK has reinforced its commitment to silent interfering RNA (siRNA) technology through a licensing agreement with Chinese biotechnology company Frontier Biotechnologies, valued at just over USD 1 billion

The pharmaceutical giant will pay Frontier USD 40 million upfront, with additional payments of up to USD 963 million tied to achieving specific development, regulatory, and commercial milestones.

In return, GSK gains access to two early-stage siRNA drug candidates targeting kidney diseases caused by inflammation.

One asset is currently in preclinical development, while the other has received Investigational New Drug (IND) approval.

Development and commercialization strategy

Under the agreement’s terms, Frontier will initially retain responsibility for advancing both candidates through early development stages.

The Chinese biotech will conduct a Phase I clinical trial in China for its IND-enabled asset while working to secure IND approval for the second candidate.

Once these milestones are achieved, GSK will assume control of global development and potential commercialization efforts for both therapies.

Frontier stands to benefit further from the partnership through tiered royalty payments on global sales if either drug successfully reaches the market.

Strategic alignment with GSK’s research focus

Kaivan Khavandi, GSK’s senior vice president and global head of research and development for respiratory, immunology, and inflammation, described the two “potential first-in-class” oligonucleotide therapies as strategically aligned with the company’s priorities in a statement released on February 23.

The company has prioritized investments in platform technologies and treatments for inflammation-driven diseases.

At the 2026 J.P. Morgan Healthcare Conference, GSK’s chief scientific officer, Tony Wood explained that early-stage research and development investments, combined with artificial intelligence applications, would help offset upcoming patent expiries within the company’s portfolio.

Growing siRNA portfolio

This Frontier deal represents GSK’s latest move to expand its siRNA pipeline.

The company previously established a USD745 million partnership with California-based Empirico to develop EMP-012, a clinical-stage siRNA therapy for chronic obstructive pulmonary disease.

GSK is also evaluating daplusiran/tomligisiran, an in-licensed hepatitis B candidate, through the Phase II B-UNITED study.

Industry-wide embrace of siRNA technology

According to GlobalData research, pharmaceutical companies are increasingly pursuing siRNA-focused licensing agreements, particularly for metabolic disorders and cancer treatments.

Chinese-developed assets feature prominently in this trend, accounting for 36% of siRNA licensing deals tracked by GlobalData’s Pharmaceutical Intelligence Center.

Novartis has similarly pursued multiple billion-dollar siRNA partnerships, including agreements with Shanghai Argo Pharmaceutical for metabolic disease candidates and with Arrowhead for a preclinical Parkinson’s disease therapy.

Meanwhile, Madrigal signed a USD 4.4 billion licensing deal with Suzhou Ribo Life Sciences, securing global rights to six siRNA-based therapies for metabolic dysfunction-associated steatohepatitis.